HC Wainwright & Co. Maintains Buy on Summit Therapeutics, Raises Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Summit Therapeutics and raised the price target from $16 to $30, indicating a positive outlook for the company's stock.
September 09, 2024 | 10:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has increased the price target for Summit Therapeutics from $16 to $30, maintaining a Buy rating. This suggests a strong positive outlook for the stock.
The increase in price target from $16 to $30 by a reputable analyst firm like HC Wainwright & Co. is a strong indicator of expected positive performance for Summit Therapeutics. The maintained Buy rating further supports this bullish sentiment.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100